Physician profile
Bryan Le Holand
NPI 1699139055
$25,726.94
in general payments reported to CMS, 2019-2025
27 companies · $1,483 in 2025
The $1,483 reported for 2025 was more than what 77% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,696 · 2020: $130 · 2021: $1,645 · 2022: $5,030 · 2023: $8,148 · 2024: $7,595 · 2025: $1,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $13K · Food and Beverage: $3,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $13,420.00 |
| Food and Beverage | $3,806.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $15,207.62 | 2022-2024 | Restrata Wound Matrix |
| Summit Surgical Corp. | $3,787.79 | 2021-2023 | |
| Medline Industries Lp | $1,204.12 | 2019 | |
| Organogenesis INC. | $1,121.78 | 2021-2025 | Puraply Wound Matrix, Apligraf, Via Matrix |
| Biowound Solutions, INC. | $595.13 | 2024-2025 | Bio-Connekt |
| Stryker Corporation | $538.17 | 2021-2025 | Ortholoc 2 Lapifuse, Citrefix, Augment Injectable |
| Smith+Nephew, INC. | $456.62 | 2019-2025 | Grafix, Collagenase Santyl |
| Zimmer Biomet Holdings, INC. | $376.41 | 2020-2023 | Stratum Foot Plating System |
| Orthofix Medical, INC. | $339.20 | 2021-2025 | Physio-Stim, Accelstim |
| Axogen | $292.92 | 2023-2024 | Avance Nerve Graft, Axoguard Nerve Cap, Axoguard Nerve Connector |
| Wright Medical Technology, INC. | $284.33 | 2019 | |
| Treace Medical Concepts, INC. | $258.86 | 2022-2023 | |
| Paragon 28, INC. | $230.91 | 2021-2022 | |
| Medtronic, INC. | $174.79 | 2021-2024 | Intellis Adaptivestim |
| Averitas Pharma INC. | $162.34 | 2023-2024 | Qutenza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $157.93 | 2023-2024 | Senza |
| Heron Therapeutics, INC. | $124.84 | 2022 | |
| Next Science LLC | $108.03 | 2022-2023 | Xperience, Blastx, Surgx |
| Mimedx Group, INC. | $68.99 | 2024-2025 | |
| Fusion Orthopedics USA, LLC | $47.79 | 2025 | |
| Reprise Biomedical, INC. | $34.17 | 2024 | Miro3d |
| Integra Lifesciences Corporation | $34.14 | 2019 | |
| Abbvie INC. | $33.01 | 2022 | |
| Amgen INC. | $25.03 | 2024 | Krystexxa |
| Zimvie INC. | $24.13 | 2022 | |
| Solventum Corporation | $20.00 | 2024 | Activ.A.C., Promogran Prisma, Snap |
| Kerecis Limited | $17.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Holand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.